On September 4, 2024, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics Inc (APGE, Financial), sold 6,665 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 280,793 shares of Apogee Therapeutics Inc.
Apogee Therapeutics Inc (APGE, Financial) is a biopharmaceutical company focused on the development and commercialization of novel therapies to treat autoimmune and inflammatory diseases.
Over the past year, the insider has sold a total of 19,995 shares and has not made any purchases. This recent sale is part of a broader trend observed within the company, where there have been 7 insider sells and no insider buys over the past year.
Shares of Apogee Therapeutics Inc were priced at $47.56 on the day of the transaction. The company's market cap is approximately $2.672 billion. This valuation reflects various financial metrics such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
The stock's valuation can also be assessed using the GF Value, a measure that provides insights into the fair value of a stock based on historical trading prices, financial ratios, and future earnings projections.
This insider sale might be of interest to investors tracking insider behaviors as an indicator of confidence in the company's future prospects. Monitoring such transactions can provide valuable insights into the strategic moves of key executives and their outlook on the company's stock.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
